Company news
Guizhou Yibai Pharmaceutical Co. Ltd. Class A (SSE:600594) news
Guizhou Yibai Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Aug 21, 2026: "Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on Resolutions…
Press releases & updates
"Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Meeting of the 9th Board of Directors
August 20, 2026
"Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on the Selection of Products in the Second Round of Follow-Up Centralized Procurement by the National Alliance for Chinese Patent Medicine Procurement
August 3, 2026
"Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on the Receipt of the "Administrative Penalty Notice" from Guizhou Provincial Drug Administration
July 31, 2026
"Guizhou Yibai Pharmaceutical Co., Ltd."Semi-annual Performance Forecast for 2026
July 14, 2026
"Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on Inclusion of the Company's Pharmaceutical Products in the "National Essential Medicines List (2026 Edition)"
July 10, 2026
"Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on the Cancellation of Repurchased Shares and the Change in Share Capital
July 9, 2026
"Guizhou Yibai Pharmaceutical Co., Ltd."Announcement on Election of Employee Representative Director
July 2, 2026
Announcement on Resolutions of the 17th Meeting of the 8th Board of Directors
June 16, 2026
Announcement on Changing the Use of Shares Repurchased and Cancellation and Notice to Creditors
May 20, 2026
Announcement on Attending 2026 Collective Reception Day for Investors of Listed Companies in Guizhou Jurisdiction and 2025 Annual Performance Briefing
April 30, 2026
Announcement on Provision for Impairment of Related Assets in 2025
April 22, 2026
Announcement on Abnormal Fluctuations in Stock Trading
April 2, 2026
Announcement on Obtaining the Drug Registration Certificate for Azacitidine for Injection
March 27, 2026
Earnings Preannouncement for 2025
January 21, 2026
Indicative Announcement on Expected Loss in Performance for 2025
January 12, 2026
Announcement on Changing Annual Audit Institution’s Signatory Certified Public Accountant
December 5, 2025
Announcement on Pledge and Pledge Release of Some Shares Held by Controlling Shareholder
November 27, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 26, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 13, 2025
Announcement on Election of Employee Representative Director
November 10, 2025
Announcement on Resolutions of the 13th Meeting of the 8th Board of Directors
October 29, 2025
Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
October 15, 2025
Announcement on Receipt of the Notice on Lifting the Suspension of Production and Sales from the Guizhou Provincial Medical Products Administration
September 17, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 5, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 27, 2025
Announcement on Progress in Capital Increase and Share Expansion of Subsidiary Guizhou Yibai Chinese Medicine Formula Granules Pharmaceutical Co., Ltd. and Acquisition of Minority Equity in a Holding Subsidiary
August 20, 2025
Announcement on Receipt of the Notice on Suspension of Production and Sales from the Guizhou Provincial Medical Products Administration
August 5, 2025
Semi-annual Earnings Preannouncement for 2025
July 14, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 16, 2025
Announcement on Attending 2025 Collective Reception Day for Investors of Listed Companies in Guizhou Jurisdiction and 2024 Annual Performance Briefing
April 30, 2025
Announcement on Renewing Engagement of Audit Institution for 2025
April 25, 2025
Announcement on the Change of Quality Control Reviewer by Audit Institution
March 28, 2025
Announcement on the Pledge and Release of Pledge of Partial Shares of Controlling Shareholders
March 20, 2025
Announcement on Release of Pledge of Partial Shares and Deferred Repurchase of Partial Shares by Shareholders
March 14, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Postponing Repurchase of Stock-pledged Repurchase Transaction
December 1, 2024
Announcement on Implementation Result of Repurchasing Shares and Share Changes
November 28, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 20, 2024
Announcement on Progress in Repurchasing Shares through Call Auction
November 1, 2024
Report for Q3 2024
October 25, 2024
Announcement on Receipt of "Decision on Administrative Supervision Measures" from Guizhou Securities Regulatory Bureau of China Securities Regulatory Commission
October 24, 2024
Announcement on Change of Financial Manager of the Company
September 6, 2024
Announcement on Convening the 2024 Semi-annual Performance Briefing
September 5, 2024
Announcement on Obtaining Drug Registration Certificate for Plerixafor Injection
September 3, 2024
Semi-annual Report 2024
August 23, 2024
Announcement on the First Repurchase of Company Shares
July 10, 2024
Semi-annual Performance Forecast of 2024
July 9, 2024
Announcement on Progress in Repurchasing Shares through Auction
July 2, 2024
Announcement on Pledge of Shares of Controlling Shareholder
June 7, 2024
Announcement on Resolutions of 1st Special Shareholders' Meeting of 2024
June 4, 2024